Medical Specialties Australasia (MSA) is able to announce that we have been awarded the exclusive distribution rights for the first mobile, connected, all-in one, Diabetes management system in Australasia. The system has been developed and is manufactured by independently owned company Cellnovo.
MSA was the first company to ever introduce insulin pump technology to the Australasian market when we launched the AutoSyringe Insulin Pump in 1983. Since then we have represented a handful of pump product lines including the Disetronic family, the Smiths Cozmo, as well as various glucose monitoring consumables.
MSA’s partnership with Cellnovo strongly represents our commitment to a ‘Gold Standard Only’ product portfolio approach. MSA Chief Executive Officer, MD, Patrick Gaynor said “This partnership with Cellnovo represents years of product analysis and ongoing communication between both companies, we feel the time is now right to launch in Australasia. MSA’s previous pump technology, the Smith’s Cozmo, was a patient favourite, and although was discontinued in 2008, we have exercised our option to wait for the leading, next generation technology in the diabetes pump space. We are confident the Cellnovo System represents this next step.” He went on to say “Cellnovo is currently participating in several artificial pancreas trials and we intend to introduce this technology to the Australasian market upon successful completion of those trials.”
The Cellnovo all-in one, Diabetes management system will be officially launched at the Annual Scientific Meeting of the Australian Diabetes Society and the Australian Diabetes Educators Association (ADS-ADEA) in Perth, August 30 – September 1 2017
For further information please email: email@example.com
For the Cellnovo press release click here
About the Cellnovo Diabetes Management System
Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time.
About Medical Specialties Australasia (MSA)
Medical Specialties Australasia Pty Ltd (MSA) is a privately and wholly owned Australian medical device distribution company and is a leader in providing innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and diabetes. MSA’s diverse product lines include diabetes infusion systems, surgical implants, venous ablation systems, vascular access products, colorectal surgery and diagnostic equipment, angiographic products and accessories, drainage products, thrombolytic products, ENT consumables. More information is available at www.msa.com.au
An independent medical technology company specialising in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo’s insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient’s condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems.
For further information please visit www.cellnovo.com